Iloprost is in front of the similar material, the inhibitor preparation for platelet activation, inhibit platelet aggregation and thrombosis is weakening. This medicine can be through the platelet receptor activation of adenylate cyclase, influence of phosphate ester enzyme activity and cell SAP calcium concentration, reduce the peripheral vascular resistance, mean arterial pressure, and increased heart rate, cardiac index and renal blood flow, promotes urinary sodium excretion. In addition, this drug has protect cells, cardiac function and anti-arrhythmic effects. According to the data reported abroad, this drug is compared with the front ring element, chemistry and biology stability is higher, can produce similar or greater antiplatelet effects. The mechanism of this drug antiplatelet characterized by activation of adenylate cyclase, thereby increasing intracellular adenosine cyclophosphate (cAMP) level, it was reported that this medicine increases the role of intracellular cAMP is top 10 times. In addition, for patients with type 2 diabetes with peripheral artery occlusion, input within this medicine can reduce the plasma fibrinolytic enzyme original activator inhibitor 1 (PAI 1) activity. PAI - 1 type can make the organization fibrin dissolve enzyme activator and urokinase type plasma, the original activator inactivation, is a kind of powerful fibrinolysis enzyme inhibitors.
Warm reminder: often have fever and headache, followed by gastrointestinal reaction, such as nausea, vomiting, abdominal pain and diarrhea. The adverse reaction of the individual difference is very big, but are related to the dose. After drug withdrawal, it quickly alleviate adverse reactions.
No comments:
Post a Comment